Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS.
BACKGROUND
To systematically review literature on use of model for end-stage liver disease (MELD) score to determine severity and prognosis of liver disease in various clinical situations and to evaluate its use in decisions regarding therapeutic interventions.


METHODS
Computerized literature searches using key medical terms; review of authors' extensive files on this subject; and personal clinical experience.


RESULTS
The MELD score, a prospectively developed and validated scale for severity of end-stage liver disease, utilizes serum bilirubin, serum creatinine, and international normalized ratio to predict mortality in cirrhotic patients. It has proven clinically useful in increasingly varied clinical situations. The United Network for Organ Sharing uses MELD scores, with bonus points assigned for hepatocellular cancer, to prioritize allocation of deceased donor livers for liver transplantation. This work reviews recent data demonstrating that MELD scores relatively accurately predict mortality in patients with variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, and acute liver failure, as well as assess risks of non-liver transplantation surgery or transjugular intrahepatic portosystemic shunts in cirrhotic patients. MELD scores fail to predict mortality in about 15% of patients with end-stage liver disease. Incorporation of additional parameters, including serum sodium level, serum albumin level, glucose intolerance, or APACHE II score, may potentially improve prognostic accuracy.


CONCLUSIONS
MELD scores relatively accurately assess severity of liver disease and prognosis in patients with advanced liver disease in general, and in patients with individual complications of liver disease. It is useful in making decisions on potential therapies. Incorporating additional parameters may further improve its prognostic accuracy.
Al Sibae
Mohamad R
MR
Division of Transplantation, Department of Surgery, William Beaumont Hospital, Royal Oak, MI 48073, USA.
Cappell
Mitchell S
MS
D001663:Bilirubin / Q000097:blood; D003404:Creatinine / Q000097:blood; D058625:End Stage Liver Disease / Q000401:mortality*; D004932:Esophageal and Gastric Varices / Q000401:mortality*; D005260:Female; D006519:Hepatitis, Alcoholic / Q000401:mortality*; D006530:Hepatorenal Syndrome / Q000401:mortality*; D006801:Humans; D008103:Liver Cirrhosis / Q000401:mortality*; D017114:Liver Failure, Acute / Q000401:mortality*; D008297:Male; D019168:Portasystemic Shunt, Transjugular Intrahepatic / Q000401:mortality; D011379:Prognosis; D011517:Prothrombin Time; D012720:Severity of Illness Index
D003404:Creatinine; D001663:Bilirubin